| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dioxins | 13 | 2022 | 17 | 2.150 |
Why?
|
| Puberty | 17 | 2022 | 59 | 2.130 |
Why?
|
| Sexual Maturation | 10 | 2019 | 52 | 2.010 |
Why?
|
| Environmental Pollutants | 13 | 2022 | 97 | 1.850 |
Why?
|
| Environmental Exposure | 18 | 2022 | 222 | 1.710 |
Why?
|
| Polychlorinated Biphenyls | 11 | 2022 | 39 | 1.610 |
Why?
|
| Leydig Cells | 5 | 2012 | 12 | 1.400 |
Why?
|
| Endocrine Disruptors | 5 | 2018 | 78 | 1.180 |
Why?
|
| Hydrocarbons, Chlorinated | 7 | 2020 | 11 | 1.110 |
Why?
|
| Child | 44 | 2023 | 4678 | 1.100 |
Why?
|
| Pesticides | 8 | 2020 | 57 | 1.080 |
Why?
|
| Testicular Hormones | 5 | 2004 | 11 | 1.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 6 | 2015 | 632 | 0.970 |
Why?
|
| Glycoproteins | 5 | 2004 | 190 | 0.920 |
Why?
|
| Down Syndrome | 3 | 2023 | 47 | 0.920 |
Why?
|
| Body Height | 6 | 2017 | 66 | 0.920 |
Why?
|
| Lead | 9 | 2022 | 45 | 0.900 |
Why?
|
| Russia | 26 | 2022 | 55 | 0.880 |
Why?
|
| Hypothyroidism | 2 | 2023 | 43 | 0.820 |
Why?
|
| Congenital Hypothyroidism | 1 | 2023 | 13 | 0.790 |
Why?
|
| Thyroid Diseases | 1 | 2023 | 30 | 0.780 |
Why?
|
| Body Composition | 2 | 2019 | 154 | 0.740 |
Why?
|
| Vitamin D | 3 | 2013 | 140 | 0.730 |
Why?
|
| Adolescent | 30 | 2024 | 6383 | 0.680 |
Why?
|
| Male | 57 | 2024 | 31073 | 0.650 |
Why?
|
| Growth | 4 | 2010 | 23 | 0.600 |
Why?
|
| Anti-Mullerian Hormone | 6 | 2012 | 68 | 0.600 |
Why?
|
| Human Growth Hormone | 2 | 2011 | 19 | 0.580 |
Why?
|
| Insulin Resistance | 2 | 2014 | 413 | 0.580 |
Why?
|
| Semen | 4 | 2024 | 50 | 0.550 |
Why?
|
| Testis | 5 | 2012 | 162 | 0.540 |
Why?
|
| Obesity | 3 | 2015 | 1268 | 0.510 |
Why?
|
| Growth Disorders | 3 | 2008 | 30 | 0.510 |
Why?
|
| Polychlorinated Dibenzodioxins | 4 | 2022 | 10 | 0.510 |
Why?
|
| Luteinizing Hormone | 4 | 2022 | 102 | 0.500 |
Why?
|
| Cell Differentiation | 3 | 2012 | 1398 | 0.490 |
Why?
|
| Blood Glucose | 3 | 2015 | 491 | 0.490 |
Why?
|
| Humans | 63 | 2024 | 65528 | 0.480 |
Why?
|
| Prospective Studies | 15 | 2024 | 3355 | 0.470 |
Why?
|
| Receptors, Transforming Growth Factor beta | 2 | 2012 | 30 | 0.450 |
Why?
|
| Receptors, Peptide | 2 | 2012 | 34 | 0.440 |
Why?
|
| Metformin | 1 | 2015 | 76 | 0.430 |
Why?
|
| Weight Gain | 3 | 2015 | 169 | 0.420 |
Why?
|
| Endosulfan | 1 | 2013 | 2 | 0.410 |
Why?
|
| Endocrine System | 1 | 2013 | 17 | 0.400 |
Why?
|
| Biomarkers | 4 | 2014 | 1471 | 0.390 |
Why?
|
| Cryptorchidism | 2 | 2003 | 20 | 0.390 |
Why?
|
| Metabolic Syndrome | 1 | 2014 | 147 | 0.390 |
Why?
|
| Growth Inhibitors | 2 | 2003 | 25 | 0.380 |
Why?
|
| Androgens | 2 | 2010 | 66 | 0.380 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type I | 1 | 2012 | 5 | 0.380 |
Why?
|
| Phthalic Acids | 2 | 2022 | 41 | 0.360 |
Why?
|
| Hormones | 2 | 2009 | 62 | 0.350 |
Why?
|
| Semen Analysis | 4 | 2024 | 20 | 0.350 |
Why?
|
| Vitamin D Deficiency | 1 | 2012 | 42 | 0.350 |
Why?
|
| Patient Simulation | 1 | 2012 | 74 | 0.350 |
Why?
|
| Computer-Assisted Instruction | 1 | 2012 | 81 | 0.340 |
Why?
|
| Growth Hormone-Releasing Hormone | 1 | 2011 | 5 | 0.340 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2011 | 11 | 0.340 |
Why?
|
| Dwarfism | 1 | 2011 | 15 | 0.340 |
Why?
|
| Parenting | 2 | 2014 | 76 | 0.340 |
Why?
|
| Vitamins | 1 | 2011 | 81 | 0.320 |
Why?
|
| Liver Diseases | 1 | 2012 | 160 | 0.320 |
Why?
|
| Parents | 2 | 2013 | 410 | 0.320 |
Why?
|
| Mentors | 1 | 2011 | 120 | 0.310 |
Why?
|
| Pseudohypoparathyroidism | 1 | 2009 | 1 | 0.310 |
Why?
|
| Female | 23 | 2018 | 34125 | 0.300 |
Why?
|
| Thyroxine | 3 | 2023 | 55 | 0.300 |
Why?
|
| Furans | 5 | 2021 | 33 | 0.300 |
Why?
|
| Hormone Antagonists | 1 | 2009 | 12 | 0.300 |
Why?
|
| Psychotic Disorders | 1 | 2011 | 164 | 0.300 |
Why?
|
| Counseling | 1 | 2012 | 378 | 0.290 |
Why?
|
| Social Support | 2 | 2014 | 389 | 0.290 |
Why?
|
| Insulin | 4 | 2015 | 693 | 0.280 |
Why?
|
| Thyroid Function Tests | 3 | 2023 | 14 | 0.280 |
Why?
|
| Antipsychotic Agents | 1 | 2011 | 307 | 0.270 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2014 | 772 | 0.270 |
Why?
|
| Infant | 6 | 2023 | 1718 | 0.270 |
Why?
|
| Young Adult | 13 | 2024 | 4836 | 0.260 |
Why?
|
| Fetus | 1 | 2007 | 103 | 0.260 |
Why?
|
| Infant, Newborn | 5 | 2023 | 1451 | 0.250 |
Why?
|
| Hexachlorobenzene | 3 | 2015 | 3 | 0.250 |
Why?
|
| Dichlorodiphenyl Dichloroethylene | 3 | 2015 | 4 | 0.250 |
Why?
|
| Virilism | 2 | 2003 | 4 | 0.250 |
Why?
|
| Cohort Studies | 9 | 2022 | 2635 | 0.250 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 555 | 0.250 |
Why?
|
| Longitudinal Studies | 7 | 2019 | 1286 | 0.250 |
Why?
|
| Testosterone | 4 | 2012 | 129 | 0.230 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 866 | 0.220 |
Why?
|
| RNA, Small Untranslated | 1 | 2024 | 19 | 0.220 |
Why?
|
| Thyrotropin | 2 | 2023 | 35 | 0.210 |
Why?
|
| Disorders of Sex Development | 1 | 2003 | 12 | 0.210 |
Why?
|
| Hypothalamic Diseases | 1 | 2023 | 1 | 0.200 |
Why?
|
| Pallister-Hall Syndrome | 1 | 2023 | 1 | 0.200 |
Why?
|
| Polydactyly | 1 | 2023 | 2 | 0.200 |
Why?
|
| Hamartoma | 1 | 2023 | 12 | 0.200 |
Why?
|
| Proteome | 1 | 2024 | 160 | 0.200 |
Why?
|
| Triptorelin Pamoate | 1 | 2003 | 1 | 0.200 |
Why?
|
| Body Mass Index | 6 | 2019 | 888 | 0.200 |
Why?
|
| Animals | 11 | 2018 | 21529 | 0.190 |
Why?
|
| Diethylhexyl Phthalate | 1 | 2022 | 4 | 0.190 |
Why?
|
| Hydatidiform Mole | 1 | 2002 | 2 | 0.180 |
Why?
|
| Hyperthyroidism | 1 | 2002 | 19 | 0.180 |
Why?
|
| Penis | 1 | 2002 | 38 | 0.180 |
Why?
|
| Protein-Arginine N-Methyltransferases | 2 | 2022 | 35 | 0.180 |
Why?
|
| Hypoglycemia | 2 | 2013 | 65 | 0.180 |
Why?
|
| Uterine Neoplasms | 1 | 2002 | 36 | 0.180 |
Why?
|
| Pharmacogenetics | 1 | 2021 | 24 | 0.170 |
Why?
|
| Child, Preschool | 6 | 2012 | 2077 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2022 | 219 | 0.170 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 376 | 0.170 |
Why?
|
| Pilot Projects | 4 | 2013 | 1020 | 0.170 |
Why?
|
| Spermatozoa | 2 | 2024 | 265 | 0.160 |
Why?
|
| Patient Education as Topic | 2 | 2014 | 483 | 0.160 |
Why?
|
| Electric Impedance | 1 | 2019 | 36 | 0.150 |
Why?
|
| Reference Values | 3 | 2006 | 331 | 0.150 |
Why?
|
| Insulin Infusion Systems | 2 | 2013 | 11 | 0.150 |
Why?
|
| Feasibility Studies | 2 | 2012 | 582 | 0.150 |
Why?
|
| Linear Models | 4 | 2013 | 409 | 0.150 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 2 | 2012 | 9 | 0.150 |
Why?
|
| Cell Count | 2 | 2012 | 133 | 0.140 |
Why?
|
| Adult | 11 | 2022 | 17418 | 0.140 |
Why?
|
| Organelle Biogenesis | 1 | 2018 | 19 | 0.140 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2018 | 34 | 0.140 |
Why?
|
| Cross-Sectional Studies | 6 | 2019 | 2699 | 0.140 |
Why?
|
| PPAR alpha | 1 | 2018 | 34 | 0.140 |
Why?
|
| Genomics | 1 | 2021 | 394 | 0.140 |
Why?
|
| Phosphoproteins | 2 | 2012 | 223 | 0.140 |
Why?
|
| Graves Disease | 1 | 2017 | 16 | 0.130 |
Why?
|
| Celiac Disease | 1 | 2017 | 19 | 0.130 |
Why?
|
| Age Factors | 5 | 2015 | 1593 | 0.130 |
Why?
|
| Arginine | 2 | 2022 | 133 | 0.120 |
Why?
|
| Gonadal Dysgenesis | 2 | 2008 | 3 | 0.120 |
Why?
|
| Body Weight | 3 | 2017 | 381 | 0.120 |
Why?
|
| Civil Rights | 1 | 2016 | 20 | 0.120 |
Why?
|
| DNA Methylation | 1 | 2018 | 305 | 0.120 |
Why?
|
| Anthropometry | 3 | 2019 | 87 | 0.110 |
Why?
|
| Mice, Knockout | 3 | 2012 | 2162 | 0.110 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 92 | 0.110 |
Why?
|
| Benzofurans | 2 | 2011 | 13 | 0.110 |
Why?
|
| Mitochondria | 1 | 2018 | 404 | 0.110 |
Why?
|
| Health Status Disparities | 1 | 2016 | 146 | 0.110 |
Why?
|
| Time Factors | 3 | 2018 | 3789 | 0.110 |
Why?
|
| Mice | 5 | 2018 | 11215 | 0.110 |
Why?
|
| Leptin | 1 | 2014 | 89 | 0.100 |
Why?
|
| Diet, Diabetic | 1 | 2014 | 13 | 0.100 |
Why?
|
| Pregnancy | 4 | 2015 | 2432 | 0.100 |
Why?
|
| Organ Size | 2 | 2004 | 173 | 0.100 |
Why?
|
| Directive Counseling | 1 | 2014 | 39 | 0.100 |
Why?
|
| Health Policy | 1 | 2016 | 198 | 0.100 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2014 | 62 | 0.100 |
Why?
|
| Double-Blind Method | 1 | 2015 | 749 | 0.100 |
Why?
|
| Rats | 2 | 2010 | 2015 | 0.100 |
Why?
|
| Liver | 1 | 2018 | 879 | 0.100 |
Why?
|
| Regression Analysis | 1 | 2014 | 500 | 0.100 |
Why?
|
| Cholesterol | 1 | 2014 | 263 | 0.100 |
Why?
|
| Postpartum Period | 1 | 2015 | 197 | 0.100 |
Why?
|
| Triglycerides | 1 | 2014 | 250 | 0.100 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2013 | 85 | 0.100 |
Why?
|
| Androstenedione | 1 | 2012 | 9 | 0.100 |
Why?
|
| Immunoassay | 1 | 2013 | 71 | 0.090 |
Why?
|
| Activin Receptors, Type I | 1 | 2012 | 15 | 0.090 |
Why?
|
| Hyperglycemia | 1 | 2013 | 105 | 0.090 |
Why?
|
| Reproductive Health | 1 | 2012 | 25 | 0.090 |
Why?
|
| Adolescent Behavior | 1 | 2014 | 195 | 0.090 |
Why?
|
| Androgen Antagonists | 2 | 2022 | 32 | 0.090 |
Why?
|
| Self Care | 1 | 2014 | 215 | 0.090 |
Why?
|
| Alanine Transaminase | 1 | 2012 | 45 | 0.090 |
Why?
|
| RNA, Messenger | 2 | 2010 | 1580 | 0.090 |
Why?
|
| Neoplasms | 1 | 2022 | 1415 | 0.090 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2022 | 148 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2012 | 328 | 0.090 |
Why?
|
| Retrospective Studies | 1 | 2023 | 6882 | 0.080 |
Why?
|
| Child Development | 1 | 2011 | 88 | 0.080 |
Why?
|
| Stimulation, Chemical | 1 | 2010 | 18 | 0.080 |
Why?
|
| Puberty, Delayed | 1 | 2010 | 3 | 0.080 |
Why?
|
| Pregnancy Complications | 1 | 2015 | 392 | 0.080 |
Why?
|
| Lead Poisoning | 1 | 2010 | 10 | 0.080 |
Why?
|
| Blotting, Northern | 1 | 2010 | 152 | 0.080 |
Why?
|
| Qualitative Research | 2 | 2014 | 750 | 0.080 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2011 | 160 | 0.080 |
Why?
|
| Steroids | 1 | 2010 | 58 | 0.080 |
Why?
|
| Socioeconomic Factors | 4 | 2016 | 800 | 0.080 |
Why?
|
| Cell Separation | 1 | 2010 | 149 | 0.080 |
Why?
|
| Growth Hormone | 1 | 2009 | 18 | 0.080 |
Why?
|
| Menarche | 1 | 2009 | 37 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 552 | 0.070 |
Why?
|
| Age of Onset | 1 | 2009 | 175 | 0.070 |
Why?
|
| Models, Animal | 1 | 2009 | 241 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 906 | 0.070 |
Why?
|
| Dibenzofurans, Polychlorinated | 2 | 2022 | 2 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p19 | 1 | 2007 | 1 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2007 | 4 | 0.070 |
Why?
|
| Gonadotrophs | 1 | 2007 | 5 | 0.070 |
Why?
|
| Aging | 2 | 2010 | 767 | 0.070 |
Why?
|
| Reproduction | 1 | 2007 | 100 | 0.060 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2007 | 157 | 0.060 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 1310 | 0.060 |
Why?
|
| Exercise | 1 | 2014 | 964 | 0.060 |
Why?
|
| Hypoglycemic Agents | 2 | 2013 | 224 | 0.060 |
Why?
|
| Chemical Industry | 1 | 2005 | 8 | 0.060 |
Why?
|
| United States | 3 | 2016 | 8130 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 743 | 0.060 |
Why?
|
| Proportional Hazards Models | 3 | 2011 | 742 | 0.060 |
Why?
|
| Multivariate Analysis | 3 | 2011 | 937 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2006 | 738 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2018 | 3482 | 0.050 |
Why?
|
| Extracellular Vesicles | 1 | 2024 | 48 | 0.050 |
Why?
|
| Mesylates | 1 | 2003 | 2 | 0.050 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 2003 | 2 | 0.050 |
Why?
|
| Cholesterol Side-Chain Cleavage Enzyme | 1 | 2003 | 4 | 0.050 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2003 | 49 | 0.050 |
Why?
|
| Phenotype | 2 | 2008 | 1242 | 0.050 |
Why?
|
| Population | 1 | 2003 | 14 | 0.050 |
Why?
|
| Clitoris | 1 | 2003 | 5 | 0.050 |
Why?
|
| Karyotyping | 1 | 2003 | 48 | 0.050 |
Why?
|
| Procarbazine | 1 | 2022 | 3 | 0.050 |
Why?
|
| Genitalia, Male | 1 | 2003 | 11 | 0.050 |
Why?
|
| Neonatal Screening | 1 | 2004 | 104 | 0.050 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2003 | 89 | 0.050 |
Why?
|
| Diet | 3 | 2013 | 539 | 0.050 |
Why?
|
| Gestational Age | 2 | 2015 | 199 | 0.050 |
Why?
|
| Gonadotropins | 1 | 2002 | 14 | 0.050 |
Why?
|
| Sertoli Cells | 1 | 2002 | 14 | 0.050 |
Why?
|
| Dibutyl Phthalate | 1 | 2022 | 3 | 0.050 |
Why?
|
| Sperm Count | 1 | 2022 | 15 | 0.050 |
Why?
|
| Bone Density | 1 | 2003 | 143 | 0.050 |
Why?
|
| Chorionic Gonadotropin | 1 | 2002 | 15 | 0.050 |
Why?
|
| Cell Division | 1 | 2003 | 457 | 0.050 |
Why?
|
| Antithyroid Agents | 1 | 2002 | 19 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2003 | 630 | 0.050 |
Why?
|
| Methylation | 1 | 2022 | 134 | 0.050 |
Why?
|
| Sperm Motility | 1 | 2022 | 50 | 0.050 |
Why?
|
| Chromatography, Liquid | 1 | 2022 | 130 | 0.040 |
Why?
|
| Thyroid Hormones | 1 | 2002 | 81 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2002 | 152 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2003 | 1576 | 0.040 |
Why?
|
| Sex Factors | 1 | 2003 | 996 | 0.040 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2021 | 74 | 0.040 |
Why?
|
| Surveys and Questionnaires | 3 | 2014 | 2783 | 0.040 |
Why?
|
| Demography | 2 | 2015 | 180 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2004 | 2211 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2021 | 127 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2019 | 77 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2002 | 1114 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 1173 | 0.030 |
Why?
|
| Mass Screening | 1 | 2004 | 706 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2021 | 384 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2022 | 1611 | 0.030 |
Why?
|
| Diet, Gluten-Free | 1 | 2017 | 6 | 0.030 |
Why?
|
| Whole Genome Sequencing | 1 | 2018 | 86 | 0.030 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2017 | 17 | 0.030 |
Why?
|
| Menstruation Disturbances | 1 | 2017 | 18 | 0.030 |
Why?
|
| Dioxins and Dioxin-like Compounds | 1 | 2017 | 1 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2019 | 301 | 0.030 |
Why?
|
| Diet, High-Fat | 1 | 2018 | 182 | 0.030 |
Why?
|
| Environmental Monitoring | 1 | 2018 | 153 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2013 | 882 | 0.030 |
Why?
|
| Logistic Models | 2 | 2011 | 1282 | 0.030 |
Why?
|
| Immunization Programs | 1 | 2016 | 14 | 0.030 |
Why?
|
| Public Health Surveillance | 1 | 2016 | 28 | 0.030 |
Why?
|
| Social Justice | 1 | 2016 | 33 | 0.030 |
Why?
|
| Culture | 1 | 2016 | 80 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2011 | 2511 | 0.030 |
Why?
|
| Disaster Planning | 1 | 2016 | 57 | 0.030 |
Why?
|
| Communication Barriers | 1 | 2016 | 70 | 0.030 |
Why?
|
| Health Care Reform | 1 | 2016 | 89 | 0.030 |
Why?
|
| Psychology | 1 | 2015 | 45 | 0.030 |
Why?
|
| Language | 1 | 2016 | 154 | 0.030 |
Why?
|
| Violence | 1 | 2016 | 171 | 0.030 |
Why?
|
| Patient Medication Knowledge | 1 | 2013 | 3 | 0.030 |
Why?
|
| Geography | 1 | 2013 | 39 | 0.030 |
Why?
|
| Ketones | 1 | 2013 | 6 | 0.030 |
Why?
|
| Spectrophotometry, Atomic | 1 | 2013 | 7 | 0.020 |
Why?
|
| Parent-Child Relations | 1 | 2014 | 67 | 0.020 |
Why?
|
| Social Determinants of Health | 1 | 2016 | 148 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2013 | 40 | 0.020 |
Why?
|
| Self-Assessment | 1 | 2013 | 60 | 0.020 |
Why?
|
| Luminescence | 1 | 2013 | 19 | 0.020 |
Why?
|
| Milk | 1 | 2013 | 47 | 0.020 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2012 | 28 | 0.020 |
Why?
|
| South Africa | 1 | 2012 | 15 | 0.020 |
Why?
|
| Environmental Pollution | 1 | 2012 | 14 | 0.020 |
Why?
|
| Estrogen Receptor alpha | 1 | 2012 | 50 | 0.020 |
Why?
|
| Phytoestrogens | 1 | 2012 | 9 | 0.020 |
Why?
|
| Focus Groups | 1 | 2014 | 322 | 0.020 |
Why?
|
| Agriculture | 1 | 2012 | 31 | 0.020 |
Why?
|
| Educational Status | 1 | 2013 | 279 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 231 | 0.020 |
Why?
|
| Risk Factors | 2 | 2015 | 5442 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2014 | 280 | 0.020 |
Why?
|
| Research Design | 1 | 2015 | 585 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2016 | 531 | 0.020 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2011 | 41 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 1635 | 0.020 |
Why?
|
| Breast Feeding | 1 | 2013 | 162 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 214 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2011 | 239 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2016 | 595 | 0.020 |
Why?
|
| Body Size | 1 | 2010 | 24 | 0.020 |
Why?
|
| Rural Population | 1 | 2012 | 225 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 511 | 0.020 |
Why?
|
| Health Behavior | 1 | 2013 | 482 | 0.020 |
Why?
|
| Health Personnel | 1 | 2014 | 394 | 0.020 |
Why?
|
| Health Surveys | 1 | 2010 | 318 | 0.020 |
Why?
|
| Genitalia | 1 | 2008 | 9 | 0.020 |
Why?
|
| Body Weights and Measures | 1 | 2008 | 33 | 0.020 |
Why?
|
| Genes, Recessive | 1 | 2008 | 54 | 0.020 |
Why?
|
| Pedigree | 1 | 2008 | 199 | 0.020 |
Why?
|
| Codon, Nonsense | 1 | 2008 | 61 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2010 | 265 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2008 | 198 | 0.020 |
Why?
|
| Point Mutation | 1 | 2008 | 165 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2018 | 3157 | 0.020 |
Why?
|
| Pituitary Gland, Anterior | 1 | 2007 | 30 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2007 | 12 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2007 | 18 | 0.020 |
Why?
|
| Massachusetts | 1 | 2013 | 2149 | 0.020 |
Why?
|
| Dogs | 1 | 2008 | 340 | 0.020 |
Why?
|
| Ribonucleoproteins | 1 | 2007 | 117 | 0.020 |
Why?
|
| Quality of Life | 1 | 2014 | 1271 | 0.020 |
Why?
|
| Base Sequence | 1 | 2008 | 1346 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2008 | 1619 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2008 | 2017 | 0.010 |
Why?
|
| Infant Welfare | 1 | 2002 | 7 | 0.010 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2002 | 13 | 0.010 |
Why?
|
| North Carolina | 1 | 2002 | 72 | 0.010 |
Why?
|
| Child Welfare | 1 | 2002 | 52 | 0.010 |
Why?
|
| Emergency Medical Services | 1 | 2002 | 272 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2005 | 2101 | 0.010 |
Why?
|
| Physicians | 1 | 2002 | 488 | 0.010 |
Why?
|
| Middle Aged | 1 | 2010 | 18266 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2002 | 5819 | 0.010 |
Why?
|